Form 6-K NOVO NORDISK AS By: July 25


Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.


UNITED STATES

SAFETY AND EXCHANGES COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

FOREIGN PRIVATE ISSUER REPORT

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

July 25, 2022

________________

NOVO NORDISK A/S

(Exact name of the Holder as specified in its charter)

Novo Allé

DK-2880, Bagsvaerd

Denmark

(Address of main executive offices)

________________

Indicate with a check mark whether the registrant files or will file annual returns under cover of Form 20-F or Form 40-F

Form 20-F [X] Form 40-F [  ]

Indicate with a check mark whether the registrant, in providing the information in this form, is also providing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ] Nope [X]

If “Yes” is checked, indicate below the file number assigned to the declarant under rule 12g-32(b):82-________

Novo Nordisk A/S – Share buyback program

Bagsværd, Denmark, July 25, 2022 – On May 3, 2022, Novo Nordisk launched a share buyback program in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and of the Council of April 16, 2014 (MAR) and Delegated Regulation (EU) 2016/1052 of March 8, 2016 (the “safe harbor rules”). This program is part of the global share buyback program of up to DKK 24 billion to be executed over a 12-month period starting on February 2, 2022.

Under the program initiated on May 3, 2022, Novo Nordisk will buy back B shares for an amount of up to DKK 4.4 billion over the period from May 4, 2022 to August 2, 2022.

Since the July 18, 2022 announcement, the following transactions have been completed:

Number of

B-shares

Medium

purchase price

Transaction

value, DKK

Accumulated, last announcement 4,524,229 3,504,384,842
July 18, 2022 90,000 842.51 75,826,055
July 19, 2022 90,000 833.89 75,050,447
July 20, 2022 90,000 835.91 75,231,514
July 21, 2022 90,000 837.46 75,370,964
July 22, 2022 85,000 840.31 71 426 128
Accumulated under the program 4,969,229 3,877,289,950

Details of each operation carried out under the share buyback program are published on novonordisk.com.

Page 2 of 2

With the transactions described above, Novo Nordisk holds a total of 17,031,351 B shares of DKK 0.20 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares of the company is 2,280,000,000, including treasury shares.

Novo Nordisk plans to repurchase B shares for an amount of up to DKK 24 billion over a 12-month period starting February 2, 2022. As of July 22, 2022, Novo Nordisk has since February 2, 2022 repurchased a total of 15 291,358 B shares at an average price of DKK 763.77 per B share equal to a transaction value of DKK 11,679,094,972

Novo Nordisk is a leading global healthcare company, founded in 1923 and based in Denmark. Our goal is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do this by paving the way for scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 49,300 people in 80 countries and markets its products in approximately 170 countries. Novo Nordisk B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

More information

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

The Internet:
www.novonordisk.com

CVR number:

24 25 67 90

Company Announcement No. 58/2022

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Holder has duly caused this report to be signed on its behalf by the undersigned, duly authorized thereto.

Date: July 25, 2022

NOVO NORDISK A/S

Lars Fruergaard Jorgensen

Chief executive officer

Comments are closed.